GS 9190: Phase IIa data

The open-label, international Phase IIa Study 196-0112 trial in 45 treatment-naïve patients with HCV genotype 1 infection showed that dual therapy with 40 mg twice-daily GS 9190 and 75 mg twice-daily ...